TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Fujifilm shares jump 15% on China coronavirus drug trial boost

Favipiravir has been effective, with no obvious side-effects, in helping coronavirus patients recover, Zhang Xinmin, an official at China's Science and Technology Ministry, told reporters at a news conference on Tuesday.

Roxanne Liu and Makiko Yamazaki (Reuters)
Tokyo, Japan/Beijing, China
Wed, March 18, 2020

Share This Article

Change Size

Fujifilm shares jump 15% on China coronavirus drug trial boost Anti-influenza Avigan Tablets produced by Japan's Fujifilm are displayed in Tokyo on Oct. 22, 2014. (AFP/Kazuhiro Nogi)

S

hares in Japan's Fujifilm Holdings Corp surged 15% on Wednesday after a Chinese official said an active ingredient of the company's Avigan anti-flu drug appeared to help coronavirus patients recover.

Avigan, also known as Favipiravir, is manufactured by a subsidiary of Fujifilm, which has a healthcare arm although it is better known for its cameras. The drug was approved for use in Japan in 2014.

Favipiravir has been effective, with no obvious side-effects, in helping coronavirus patients recover, Zhang Xinmin, an official at China's Science and Technology Ministry, told reporters at a news conference on Tuesday.

But a Fujifilm spokesman said the company expects no direct earnings impact from potential sales growth of Favipiravir in China, at least for now, as its license for the key ingredient in the country already expired last year.

In Japan, Fujifilm manufactures Avigan only on receiving orders from the government and has no sales target for the drug, she said.

Fujifilm shares closed Wednesday up 15.4% at their daily limit high of 5,238 yen.

Fujifilm's company logo (top) is seen at its exhibition hall nearby the headquarters of Fujifilm Holdings Corp in Tokyo, Japan June 12, 2017.
Fujifilm's company logo (top) is seen at its exhibition hall nearby the headquarters of Fujifilm Holdings Corp in Tokyo, Japan June 12, 2017. (REUTERS/Kim Kyung-Hoon)

In a clinical trial in Shenzhen involving 80 participants, patients who took Favipiravir showed greater chest improvement and took less time to test negative for the genomic trace of the virus, compared with patients not given the drug, Zhang said.

First developed by Fujifilm Toyama Chemical Co Ltd, the drug has been approved for manufacturing in China by Zhejiang Hisun Pharmaceutical Co Ltd for use against new or recurring influenza in adults, the Chinese drugmaker said in a filing last month.

In 2016, the Japanese government supplied Favipiravir as an emergency aid to counter the Ebola virus outbreak in Guinea. 

 

{

Your Opinion Matters

Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.

Enter at least 30 characters
0 / 30

Thank You

Thank you for sharing your thoughts. We appreciate your feedback.